Quince Therapeutics shares are trading lower after the company reported that its Phase 3 NEAT clinical study of dexamethasone sodium phosphate encapsulated in autologous erythrocytes failed to meet statistical significance and key secondary endpoint of improvement in Clinical Global Impression of Severity.